Consensus Legend Biotech Corporation

Equities

LEGN

US52490G1022

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-09-18 EDT			5-day change	1st Jan Change
49.91 ^USD	-2.46%		+0.22%	-17.05%

09-04	Transcript : Legend Biotech Corporation Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-04-2024 02:35 PM
08-27	Legend Biotech Says China's National Medical Products Administration Approves Cell Therapy Product to Treat Multiple Myeloma	MT

Evolution of the Average Target: Legend Biotech Corporation

Evolution of the Target Price: Legend Biotech Corporation

Changes in Analyst Recommendations: Legend Biotech Corporation

a68267ca11629899b9.0Qg9pIu8NWOFnrgsKem0YLCZBMsRhNGP2hmXphMN8YY.vnF29sbLAyTo_9lzG7vMM9apRqJ7yKC66Evu8F1skurkfXjc8spDE-72_Q~871ce5dd0deccde15df6903316ed1e68

Analysts' recommendations: Legend Biotech Corporation

TD Cowen Adjusts Legend Biotech Price Target to $67 From $71, Maintains Buy Rating	07-15	MT
Truist Securities Initiates Legend Biotech With Buy Rating, $88 Price Target	06-17	MT
HC Wainwright Adjusts Legend Biotech Price Target to $73 From $86, Maintains Buy Rating	05-24	MT
Deutsche Bank Starts Legend Biotech With Buy Rating	05-24	MT
HC Wainwright Adjusts Price Target on Legend Biotech to $86 From $87, Keeps Buy Rating	05-14	MT
RBC Adjusts Price Target on Legend Biotech to $86 From $85 on Model Updates, Maintains Outperform Rating	05-14	MT
Scotiabank Upgrades Legend Biotech to Sector Outperform From Sector Perform, Price Target is $65	04-17	MT
Cantor Fitzgerald Initiates Legend Biotech With Overweight Rating	04-03	MT
UBS Adjusts Legend Biotech Price Target to $81 From $76, Maintains Buy Rating	03-18	MT
Raymond James Starts Legend Biotech With Outperform Rating, $86 Price Target	03-13	MT
RBC Trims Price Target on Legend Biotech to $85 From $86, Keeps Outperform Rating	01-03	MT
Scotiabank Initiates Legend Biotech With Sector Perform Rating, $65 Price Target	12-19	MT
HC Wainwright Raises Price Target on Legend Biotech to $87 From $86, Keeps Buy Rating	11-15	MT
HC Wainwright Adjusts Price Target on Legend Biotech to $86 From $85, Keeps Buy Rating	23-10-18	MT
Barclays Adjusts Price Target on Legend Biotech to $93 From $92, Maintains Overweight Rating	23-10-18	MT
Barclays Adjusts Price Target on Legend Biotech to $92 From $90, Maintains Overweight Rating	23-07-21	MT
HC Wainwright Adjusts Price Target on Legend Biotech to $85 From $82, Maintains Buy Rating	23-07-21	MT
Morgan Stanley Raises Price Target on Legend Biotech to $85 From $65, Maintains Overweight Rating	23-07-20	MT
BTIG Raises Price Target on Legend Biotech to $90 From $85, Maintains Buy Rating	23-06-13	MT
HC Wainwright Adjusts Legend Biotech Price Target to $82 From $77, Maintains Buy Rating	23-06-06	MT
William Blair Initiates Legend Biotech at Market Perform	23-05-25	MT
Daiwa Securities Initiates Legend Biotech at Buy Rating	23-05-22	MT
Barclays Adjusts Price Target on Legend Biotech to $90 From $65, Keeps Overweight Rating	23-05-19	MT
RBC Boosts Price Target on Legend Biotech to $83 From $74, Cites Greater Confidence in Manufacturing Progress, Keeps Outperform Rating	23-05-19	MT
BMO Capital Adjusts Price Target on Legend Biotech to $90 From $79, Maintains Outperform Rating	23-04-25	MT

More recommendations

Sector Comparison:

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Analyst Opinion	4m Revision of opinion	Divergence of analysts' opinions	Divergence of Target Price	Ecart obj. / dr
	LEGEND BIOTECH CORPORATION					+62.07%
	VERTEX PHARMACEUTICALS INCORPORATED					+5.93%
	REGENERON PHARMACEUTICALS, INC.					+1.35%
	ARGENX SE					+5.99%
	BIONTECH SE					-6.66%
	BEIGENE, LTD.					+38.20%
	SUMMIT THERAPEUTICS INC.					+13.21%
	GENMAB A/S					+35.77%
	WUXI APPTEC CO., LTD.					+46.89%
	VAXCYTE, INC.					+24.20%
	Average					+22.70%
	Weighted average by Cap.					+10.43%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

51.17USD

Average target price

82.93USD

Spread / Average Target

+62.07%

High Price Target

95.00USD

Spread / Highest target

+85.66%

Low Price Target

60.00USD

Spread / Lowest Target

+17.26%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Truist Securities
HC Wainwright
Deutsche Bank Securities
RBC Capital Markets
Scotiabank
Cantor Fitzgerald
UBS
Raymond James
Barclays
Morgan Stanley
BTIG
William Blair & Co.
Daiwa Securities
BMO Capital
JPMorgan Chase
Piper Sandler
Cowen
Guggenheim